Additionally, our discussion of APR-246 (Eprenetapopt) in correcting structural p53 mutations—especially in the context of PD-L1 downregulation in MDS—extends previous work by integrating its immunologic consequences, which had not been comprehensively addressed in earlier literature. This evidence concerns the gene TP53 and myelodysplastic syndrome.